FDA Approves First Oral Liquid Imatinib for Certain Cancers

By Amanda Nakhul, Biomedical Sciences c/o 2027

Precision is key in multiple aspects of our lives, including medicine. Diseases such as cancer, a disease in which abnormal cells divide uncontrollably and destroy body tissue, can be treated with imatinib. The FDA recently approved the first oral liquid formulation of imatinib: a revolutionary drug redefining cancer treatment. This presents an opportunity to patients who struggle with taking traditional pills due to their age, physical condition, or other obstacles.

According to the FDA, Imatinib (Imkeldi oral solution) was approved on November 22nd, 2024, and “this approved drug for pediatric indication was broadened or modified over time to extend the pediatric age group or approve the drug for a new line of therapy or disease.¹ By extending the pediatric indications, imatinib illustrates a therapeutic dynamic from the initial use in a wider variety of indications and patient populations. This evolution underlines the importance of continuous research efforts and regulatory flexibility in keeping lifesaving treatments up to date and accessible for those who will derive most benefit. New formats of approved therapy and diseases further indicate that imatinib is an efficacious drug versatile in use, especially since it would target emerging medical challenges and, therefore, a cornerstone for targeted therapy in cancer.

Moreover, this oral liquid form of imatinib provides more accuracy when it comes to dosage and can help decrease or prevent cancer growth.¹ This includes “CML, acute lymphoblastic leukemia (ALL), myelodysplastic syndrome /myeloproliferative disease (MDS/MPD), and GIST.² Accurate dosing is vital for treating these conditions as successful treatment depends on maintaining optimal and ideal drug levels to suppress cancer growth. This directly preserves and betters a patient’s quality of life. This development also reflects a curated patient centered approach to treatment, highlighting the importance of innovation in improving treatment efficiency.

However, the oral liquid imatinib advantages should not suppress the inevitable risks. Liquid preparations are inconvenient concerning storage or stability due to the human factor in their preparation and handling. Even though they’re spared the step of compounding, liquid preparations can be easily contaminated when not handled with proper care. Despite the proven clinical benefits of imatinib, patient adherence can be challenging, underscoring a critical unmet need for a more accessible, patient-friendly oral solution delivery system.³

In conclusion, the FDA approval of the first oral liquid Imatinib for certain cancers is a steppingstone in medicine and pharmaceutical care. This sets a foundation for the future of cancer treatment and is one of the many ways of slowing down one of the leading causes of death in the world.

References:

1. Commissioner O of the. Pediatric Oncology Drug Approvals. FDA. Published online July 18, 2022. https://www.fda.gov/about-fda/oncology-center-excellence/pediatric-oncology-drug-approvals

2. FDA Approves Oral Liquid Imatinib to Treat Patients With Leukemia and Other Cancer Types. Ascopost.com. Published 2025. Accessed January 22, 2025. https://ascopost.com/news/november-2024/fda-approves-oral-liquid-imatinib-to-treat-patients-with-leukemia-and-other-cancer-types

3. Sava J. FDA Approves First Oral Liquid Imatinib for Leukemia and Other Cancers. Targeted Oncology. Published November 25, 2024. Accessed January 22, 2025. https://www.targetedonc.com/view/fda-approves-first-oral-liquid-imatinib-for-leukemia-and-other-cancers